Doxil®--the first FDA-approved nano-drug: lessons learned.

Explore this paper's citation graph

Summary

This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles.

Type
review
Published
2012-06-10
Cited by
4,286
References
134

Keywords

Liposome, Drug, Pharmacology, Medicine, Doxorubicin

References

Cited by

Related papers